The backlash over surging drug prices is starting to take hold.
Employers in the U.S. probably added more than 200,000 jobs for a fourth straight month in May, highlighting further progress in the labor market, data in the coming week may show.
Dendreon Inc. ’s $93,000 price tag for its Provenge prostate cancer treatment must be covered under the rules of the U.S. Medicare health plan, according to a letter submitted by the American Society of Clinical Oncology .
Abraxis BioScience Inc. ’s drug Abraxane benefitted more than one-third of pancreatic-cancer patients who didn’t respond to a standard treatment, a study found.
Pinpointing the genetic changes that cause cancer has been a focus of researchers for more than a decade. Now, top cancer hospitals are making genetic testing a new standard of care in the field.
Middle-aged men who stayed fit were less likely to die from three common cancers after being diagnosed than those who were out of shape, research found.